Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sha Sha, Lina Ren, Xiaona Xing, Wanshu Guo, Yan Wang, Ying Li, Yunpeng Cao, Le Qu
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2026-02-01
Series:	Neural Regeneration Research
Subjects:	alzheimer’s disease amyloid deposits amyloid-beta antibody cognitive dysfunction dementia immunotherapy oligomer preventive immunization tau hyperphosphorylation
Online Access:	https://journals.lww.com/10.4103/NRR.NRR-D-24-00846
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
by: Alexandra Wicker, et al.
Published: (2024-10-01)

Cutibacterium Acnes induces Alzheimer’s disease-like pathology in brains of wistar rats through structural changes associated with microtubules
by: Morteza Aliashrafi, et al.
Published: (2024-11-01)

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
by: Cynthia J. Siebrand, et al.
Published: (2025-05-01)

The relationship between postoperative delirium and plasma amyloid beta oligomer
by: YoungSoon Yang, et al.
Published: (2025-04-01)

Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
by: Xifeng Wang, et al.
Published: (2024-10-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Analysis of cognitive status of Alzheimer’s disease’s subjects and its association with biomarkers (amyloid beta and tau proteins) using NACC data
by: Vaghawan Prasad Ojha, et al.
Published: (2025-04-01)

Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy
by: Shiwani Randhawa, et al.
Published: (2025-04-01)

The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity
by: Julia Ring, et al.
Published: (2022-04-01)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
by: Michael Ewers, et al.
Published: (2020-08-01)

Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies
by: Yunkwon Nam, et al.
Published: (2025-03-01)

Sleep reduces CSF concentrations of beta-amyloid and tau: a randomized crossover study in healthy adults
by: Tim Lyckenvik, et al.
Published: (2025-08-01)

Strategies for Treating Alzheimer’s: Current Approaches and Future Perspectives
by: Adriana Skuba, et al.
Published: (2025-05-01)

Impaired glymphatic clearance is an important cause of Alzheimer’s disease
by: Iyawnna Hazzard, et al.
Published: (2024-10-01)

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients
by: Hyuk Sung Kwon, et al.
Published: (2025-03-01)

Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
by: Daniela Dias, et al.
Published: (2025-01-01)

Nitroxyl Hybrids with Curcumin and Stilbene Scaffolds Display Potent Antioxidant Activity, Remodel the Amyloid Beta Oligomer, and Reverse Amyloid Beta-Induced Cytotoxicity
by: Madhu S. Budamagunta, et al.
Published: (2024-11-01)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025-04-01)

The mechanism underlying streptozotocin injection for the development of a nontransgenic Alzheimer's disease animal model
by: Nurina Titisari, et al.
Published: (2025-02-01)

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
by: Giulia Musso, et al.
Published: (2025-08-01)

Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model
by: Kunie Ando, et al.
Published: (2025-01-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Amyloid is associated with accelerated atrophy in cognitively unimpaired individuals
by: Henry Gilreath Stephenson, et al.
Published: (2025-01-01)

The Potential Mechanism and the Role of Antioxidants in Mitigating Oxidative Stress in Alzheimer’s Disease
by: Rayees Ahmad Naik, et al.
Published: (2025-02-01)

Testing the causal impact of plasma amyloid on total Tau using a genetically informative sample of adult male twins
by: Nathan A. Gillespie, et al.
Published: (2025-01-01)

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease
by: Davina Biel, et al.
Published: (2023-01-01)

Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective
by: Dhamidhu Eratne, et al.
Published: (2024-12-01)

Blood essential trace elements and Alzheimer’s disease biomarkers in midlife
by: Xin Wang, et al.
Published: (2025-05-01)

Screening of Aβ and phosphorylated tau status in the cerebrospinal fluid through machine learning analysis of portable electroencephalography data
by: Masahiro Hata, et al.
Published: (2025-01-01)

Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models
by: Xiyan Rui, et al.
Published: (2024-12-01)

Associations of Plasma and CSF Osteocalcin Levels With CSF ATN Biomarkers and Cognitive Functions in Alzheimer's Disease
by: Xian‐Le Bu, et al.
Published: (2025-07-01)

Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy
by: Eun Hee Ahn, et al.
Published: (2025-01-01)

Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study
by: Emily Rosenich, et al.
Published: (2025-07-01)

Immune cell responses to amyloid-beta proteins: What is the extent and implications of amyloid-beta induced cytotoxicity in microglial cells and peripheral blood mononuclear cells?
by: Cao, A.
Published: (2017-07-01)

Elevated 24-hydroxycholesterol levels counteract okadaic acid-induced tau hyperphosphorylation and neuronal morphology impairment
by: Serena Giannelli, et al.
Published: (2025-10-01)

Small-Molecule Inhibitors of Amyloid Beta: Insights from Molecular Dynamics—Part A: Endogenous Compounds and Repurposed Drugs
by: Mariyana Atanasova
Published: (2025-02-01)

miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain
by: Evgenia Salta, et al.
Published: (2016-08-01)

Autophagy and Alzheimer’s Disease: Mechanisms and Impact Beyond the Brain
by: Zaw Myo Hein, et al.
Published: (2025-06-01)

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01)

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein
by: Jingfeng Liang, et al.
Published: (2025-08-01)